Endocrinology and PD: Optimal treatment of anemia in peritoneal dialysis patients

Peritoneal Dialysis International

Volumn 16, Issue SUPPL. 1, 1996, Pages

  Bárány, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anemia; Chronic renal failure; Erythropoietin

Indexed keywords

ANTIANEMIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; DRUG EFFICACY; EXERCISE; HEART FUNCTION; HEART INDEX; HUMAN; HYPERTENSION; IMMUNE STATUS; META ANALYSIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION; VASCULAR RESISTANCE;

EID: 0029890724     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089601601s49     Document Type: Conference Paper

References (65)

1. Ratcliffe PJ, Ebert BL, Ferguson DJP, et al. Regulation of the erythropoietin gene. Nephrol Dial Transplant 1995; 10(Suppl 2):18-27.
2. Jolliffe LK, Middleton SA, Barbone FP, et al. Erythropoietin receptor: application in drug development. Nephrol Dial Transplant 1995; 10(Suppl 2): 28-34.
3. Eschbach JW. The future of r-HuEPO. Nephrol Dial Transplant 1995; 10(Suppl 2):96-109.
4. Geerlings W, Morris RW, Brunner FP, et al. Factors influencing anaemia in dialysis patients. A special survey by the EDTA-ERA Registry Nephrol Dial Transplant 1993; 8:585-9.
5. Chandra M, Clemons GK, McVicar M, et al. Serum erythropoietin levels and hematocrit in end-stage renal disease: influence of the mode of dialysis. Am J Kidney Dis 1988; 12:208-13.
6. Zappacosta AR, Caro J, Erslev A. Normalization of hematocrit in patients with end-stage renal disease on continuous ambulatory peritoneal dialysis. Am J Med 1982; 72:53-7.
7. McGonigle RJS, Husseri F, Wallin JD, Fischer JW. Hemodialysis and continuous ambulatory peritoneal dialysis effects on erythropoiesis in renal failure. Kidney Int 1984; 25:430-6.
8. Korbet SM. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int 1993; 43:(Suppl 40):S111-119.
9. Nissenson AR. Erythropoietin treatment in peritoneal dialysis patients. Perit Dial Int 1994; 14(Suppl 3): S63-69.
10. USRDS 1994 Annual Data Report. Erythropoietin use in dialysis patients. Am J Kidney Dis 1994; 24(Suppl 2):S69-73.
11. Zachée P, Van Rompuy W. Correcting the anaemia of end-stage renal failure with recombinant human erythropoietin (r-HuEPO): the Benelux experience. Erythropoiesis: New Dimensions in the Treatment of Anaemia 1994; 5:51-7.
12. Cotes PM, Pippard MJ, Reid CDL, et al. Characterization of the anemia of chronic renal failure and the mode of its correction by a preparation of human erythropoietin (r-HuEPO). An investigation of the pharmacokinetics of intravenous erythropoietin and its effects on erythrokinetics. Q J Med 1989; 70:113-37.
13. Flaharty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47:557-64.
14. Lui SF, Chung WWM, Leung CB, et al. Pharmacokinetic and pharmacodynamics of subcutaneous and intraperitoneal administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1990; 33:47-51.
15. Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1:425-7.
16. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990; 76:1718-22.
17. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol 1990; 66:83-6.
18. Halstenson C, Macres M, Katz SA, et al. Comparative Pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50:702-12.
19. Macdougall IC, Jones JM, Robinson MI, et al. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 1991; 88:152-6.
20. Bargman JM, Jones JE, Petro JM. The pharmacokinetics of intraperitoneal erythropoietin administered undiluted or diluted in dialysate. Perit Dial Int 1992; 12:369-72.
21. Frenken LAM, Struijk DK, Coppens PJW, et al. Intraperitoneal administration of recombinant human erythropoietin. Perit Dial Int 1992; 12:378-83.
22. Lai KN, Lui SF, Leung JCK, et al. Effect of subcutaneous and intraperitoneal administration of recombinant human erythropoietin on blood pressure and vasoactive hormones in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 57:394-400.
23. Nasu T, Mitui H, Shinohara Y, et al. Effect of erythropoietin in continuous ambulatory peritoneal dialysis patients: comparison between intravenous and intraperitoneal administration. Pent Dial Int 1992; 12:373-7.
24. Nissenson AR. Erythropoietin and peritoneal dialysis: the efficacy of intraperitoneal dosing. Perit Dial Int 1992; 12:350-2.
25. Frenken LAM, van Lier HJJ, Gerlag PGG, et al. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. Br Med J 1992; 303:288.
26. Granolleras C, Leskopf W, Shaldon S, Fourcade J. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991; 36:294-8.
27. Abraham PA, St Peter WL, Redic-Kill KA, Halstenson CE. Controversies in determination of epoetin (recombinant human erythropoietin) dosages. Clin Pharmacokinet 1992; 22:409-15.
28. Besarab A, Flaharty KK, Erslev AE, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol 1991; 2:1405-16.
29. Macdougall IC. How to get the best out of r-HuEPO. Nephrol Dial Transplant 1995; 10 (Suppl 2):85-91.
30. Zimmerman SW, Johnson CA. Erythropoietin use in peritoneal dialysis patients. Am J Kidney Dis 1991; 18(Suppl 1):38-41.
31. Cheng IKP, Cy C, Chan MK, et al. Correction of anemia in patients on continuous ambulatory peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study. Clin Nephrol 1991; 35:207-12.
32. Eisele G, Bailie GR, Clement C, Wong E. Erythropoietin in continuous ambulatory peritoneal dialysis: experience with subcutaneous administration. Perit Dial Int 1992; 12:34-6.
33. Hughes RT, Cotes PM, Pippard MJ, et al. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment. Br J Haematol 1990; 75:268-73.
34. Lui SF, Law CB, Ting SM, et al. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1991; 36:246-51.
35. Macdougall IC, Davies ME, Hutton RD, et al. The treatment of renal anaemia in CAPD patients with recombinant human erythropoietin. Nephrol Dial Transplant 1990; 5:950-5.
36. Sinai-Trieman L, Salusky IB, Fine RN. Use of subcutaneous recombinant human erythropoietin in children undergoing continuous cyclic peritoneal dialysis. J Pediatr 1989; 114:550-4.
37. Steinhauer HB, Lubrich-Birkner I, Dreyling KW, Schollmeyer P. Effect of human recombinant erythropoietin on anaemia and dialysis efficiency in patients undergoing continuous ambulatory peritoneal dialysis. Eur J Clin Invest 1991; 21:47-52.
38. Stevens JM, Auer J, Strong CA, et al. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1991; 6:487-94.
39. Saleh A, Krane NK, Caballero M, Starke E. Once weekly subcutaneous erythropoietin is an effective maintenance therapy in the treatment of anemia of end stage renal disease in patients on CAPD. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in peritoneal dialysis. Toronto: Peritoneal Dialysis Bulletin Inc., 1991; 7:288-91.
40. Faller B, Slingeneyer A, Waller M, et al. Daily subcutaneous administration of recombinant human erythropoietin (rh-EPO) in peritoneal dialysis patients: a European dose-response study. Clin Nephrol 1993; 40:168-75.
41. Nomoto Y, Kawaguchi Y, Kubota M, et al. Amulticenter study with once a week or once every two weeks high-dose subcutaneous administration of recombinant human erythropoietin in continuous ambulatory peritoneal dialysis. Perit Dial Int 1994; 14:56-60.
42. Nissenson AR, Korbet S, Faber M, et al. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5:1517-29.
43. Bárány P, Clyne N, Hylander B, et al. Subcutaneous epoetin beta in renal anemia: an open multicenter dose titration study of patients on continuous peritoneal dialysis. Perit Dial Int 1995; 15:54-60.
44. Hörl WH. Optimal route of administration of erythropoietin in chronic renal failure patients: intravenous versus subcutaneous. Acta Haematol 1992; 87 (Suppl 1):16-19.
45. Drüeke TB. R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Tansplant 1995; 10(Supp 2):62-8.
46. Danielson B. R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 1995; 10 (Suppl 2): 69-73.
47. Raja R, Bloom E, Goldstein M, Johnson R. Erythropoietin with oral iron in peritoneal and hemodialysis patients - a comparison in an inner city population. ASAIO J 1993; 39:M578-M580.
48. Birgegård G. Erythropoiesis and inflammation.Contrib Nephrol 1989; 76:330-41.
49. Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE. The role of aluminum and parathyroid hormone in erythropoietin resistance in haemodialysis patients. Nephrol Dial Transplant 1991; 6:342-5.
50. Rao DS, Shih M-S, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response of erythropoietin in uremia. N Engl J Med 1993; 328:171-5.
51. Sundal E, Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in a European multicentre study of 150 haemodialysis-dependent patients.Nephrol Dial Transplant 1989;4:979-87.
52. Mann JFE. Hypertension and cardiovascular effects - long-term safety and potential long-term benefits of r-HuEPO.Nephrol Dial Transplant 1995; 10 (Suppl 2): 80-4.
53. Walls J. Haemoglobin - is more better? Nephrol Dial Transplant 1995; 10 (Suppl 2):56-61.
54. Korbet SM, Vonesh EF, Firanek CA. The effect of hematocrit on peritoneal transport. Am J Kidney Dis 1995; 18:573-8.
55. Hutchison AJ, Ofsthun NJ, Howarth D, Gokal R. The effect of haemoglobin concentration on peritoneal mass transfer and drain volumes in continuous ambulatory peritoneal dialysis. Perit Dial Int 1992; 12:230-3.
56. Taylor JE, Mactier RA, Henderson IS, et al. Dialysis efficiency in continuous ambulatory peritoneal dialysis patients treated with erythropoietin. Perit Dial Int 1992; 12:221-6.
57. Heimbürger O, Bárány P, Tranæus A, et al. Peritoneal transport and EPO. Dialysis and Transplant 1994; 23:130-6.
58. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300:573-8.
59. McMahon LP, Johns JA, McKenzie A, et al. Haemodynamic changes and physical performance at comparative levels of haemoglobin after long-term treatment with recombinant erythropoietin. Nephrol Dial Transplant 1992; 7:1199-206.
60. McMahon LP, Dawborn JK. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992; 12:162-9.
61. Bárány P, Svedenhag J, Freyschuss U, Bergström J. Physiological effects of correcting anemia in hemodialysis patients to a normal hemoglobin concentration (Abstract). Clinical Investigator 1994; 72:5B13.
62. Auer J, Simon G, Stevens J, et al. Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia.Périt Dial Int 1992; 12:40-2.
63. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. Scand J Med Sci Sports 1991; 1:88-93.
64. Bárány P, Freyschuss U, Pettersson E, Bergström J. Treatment of the anaemia in haemodialysis patients with erythropoietin: long-term effects on exercise capacity. Clin Soi 1993; 84:441-7.
65. Moore GE, Parsons DB, Stray-Gunderson J, et al. Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis 1993; 22:277-87.